Sanofi Takes Another Step Forward In MS, Files Lemtrada NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi is seeking a six-month priority review for the multiple sclerosis drug Lemtrada, positioning it for a potential launch by the end of the year. Meanwhile, FDA action on Aubagio is expected in June.